Attached files
| file | filename |
|---|---|
| 10-K - 10-K - NPS PHARMACEUTICALS INC | form10k.htm |
| EX-21.1 - SUBSIDIARIES - NPS PHARMACEUTICALS INC | exh21-1.htm |
| EX-31.1 - CEO CERTIFICATE - NPS PHARMACEUTICALS INC | exh31-1.htm |
| EX-32 - 906 CERTIFICATE - NPS PHARMACEUTICALS INC | exh32.htm |
| EX-12.1 - STATEMENT REGARDING COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES - NPS PHARMACEUTICALS INC | exh12-1.htm |
| EXCEL - IDEA: XBRL DOCUMENT - NPS PHARMACEUTICALS INC | Financial_Report.xls |
| EX-31.2 - CFO CERTIFICATE - NPS PHARMACEUTICALS INC | exh31-2.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
NPS Pharmaceuticals, Inc.:
We consent to incorporation by reference in the registration statements (Nos. 333-79622, 333-17521, 333-124821, 333-126823, 333-159363, 333-168533, 333-188491, 333-176012, 333-195805 and 333-195804) on Form S-8 and (Nos. 333-146235 and 333-190494) on Form S-3 of NPS Pharmaceuticals, Inc. of our reports dated February 18, 2015, with respect to the consolidated balance sheets of NPS Pharmaceuticals, Inc. and subsidiaries as of December 31, 2014 and 2013, and the related consolidated statements of operations, comprehensive loss, stockholders' equity (deficit), and cash flows for each of the years in the three-year period ended December 31, 2014, and the effectiveness of internal control over financial reporting as of December 31, 2014, which reports appear in the December 31, 2014 annual report on Form 10-K of NPS Pharmaceuticals, Inc.
/s/ KPMG LLP
Short Hills, New Jersey
February 18, 2015